Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell therapy, raising the efficacy bar in many forms of the disease. But the ...
UK start-up Complement Therapeutics has raised an impressive €72 million ($79 million) in first-round financing that will be used to take a gene therapy for sight-robbing disease geographic atrophy ...
Q4 2025 Earnings Call March 13, 2026 8:30 AM EDTCompany ParticipantsSimon Cairns - Chief Executive OfficerMichael Amaro ...
Earnings call illumin reported Q4 revenue of CAD 43.1M (down 13.6% YoY, up 12.8% QoQ) and FY25 revenue of CAD 143.6M (up 2.3% YoY), driven by 48% YoY Exchange growth and sequential self-service ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results